Citius Oncology's LYMPHIR Shows Early Promise in Gynecologic Cancer Trial

Event summary

  • Citius Oncology's LYMPHIR (denileukin diftitox-cxdl) showed a 24% objective response rate in a Phase 1 combination study with pembrolizumab for relapsed/refractory gynecologic malignancies.
  • The study, led by UPMC Magee-Women's Hospital, will be presented at the 2026 ASCO Annual Meeting.
  • LYMPHIR demonstrated a favorable safety profile with a median duration of response of 21.1 months in responders.
  • The trial was investigator-initiated and not designed to evaluate long-term efficacy.

The big picture

Citius Oncology is exploring LYMPHIR's potential beyond its approved use in cutaneous T-cell lymphoma (CTCL), targeting a significant unmet need in gynecologic cancers where current immunotherapies show limited efficacy. The Phase 1 data suggest LYMPHIR may enhance the effectiveness of PD-1 inhibitors like pembrolizumab by depleting regulatory T-cells, a strategy that could reshape treatment paradigms for difficult-to-treat tumors. The company's ability to secure additional clinical validation will be critical in determining LYMPHIR's long-term commercial viability.

What we're watching

Clinical Validation
Whether LYMPHIR's early promise in gynecologic cancers can be replicated in larger, controlled studies.
Commercial Strategy
How Citius Oncology plans to leverage these data to expand LYMPHIR's approved indications beyond CTCL.
Competitive Positioning
The pace at which Citius can differentiate LYMPHIR in a crowded immuno-oncology market.